Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Digital health tools

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Frontal lobe degeneration of non-Alzheimer type (FLD) is the second most common primary degenerative dementia in southern Sweden. Clinical findings in 30 FLD cases with postmortem-verified diagnoses are described. FLD starts in the presenium with a mean disease duration of 7.5 years (range 3-17 years). Clinical onset is insidious and slow and the early stage is dominated by personality changes with lack of insight and judgement and signs of disinhibition. A typical feature is progressive loss of expressive speech with stereotyped phrases, late mutism and amimia. Restlessness, changes of oral/dietary behavior and utilization behavior are prevalent as also psychotic features. Temporal and spatial orientation are usually preserved for a long time in contrast to Alzheimer's disease. Dementia in FLD is similar to that of Pick's disease and ALS with dementia. Early recognition of FLD seems possible based on standardized clinical evaluation supported by neuropsychological tests, measurement of regional cerebral blood flow and other types of brain imaging. The etiology of FLD is unknown but a positive heredity was reported in 60%.

What this study adds

Evidence grade: Low

This clinical description of 30 cases of frontal lobe degeneration of non-Alzheimer type reports that early recognition may be possible using clinical evaluation, neuropsychological tests, and brain imaging. It describes a dementia distinct from Alzheimer's disease and does not test any treatment, cure, or prevention for Alzheimer's.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gustafson, L. (1993). Clinical picture of frontal lobe degeneration of non-Alzheimer type. Dementia (Basel, Switzerland). https://doi.org/10.1159/000107313

Vancouver

Gustafson L. Clinical picture of frontal lobe degeneration of non-Alzheimer type. Dementia (Basel, Switzerland). 1993. doi:10.1159/000107313. PMID: 8401782.

BibTeX

@article{gustafson1993-8401782,
  author  = {Gustafson, L.},
  title   = {{Clinical picture of frontal lobe degeneration of non-Alzheimer type}},
  journal = {Dementia (Basel, Switzerland)},
  year    = {1993},
  doi     = {10.1159/000107313},
  pmid    = {8401782},
  url     = {https://doi.org/10.1159/000107313}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This clinical description of 30 cases of frontal lobe degeneration of non-Alzheimer type reports that early recognition may be possible using clinical evaluation, neuropsychological tests, and brain imaging. It describes a dementia distinct from Alzheimer's disease and does not test any treatment, cure, or prevention for Alzheimer's.

Study details

How this study scored 41/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 39 of the 96 points it could be judged on, which is 41 of 100. Total 41 of 100.39 of the 96 points we could judge = 41 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 39 of the 96 points we could judge it on, which is 41 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Dementia (Basel, Switzerland))
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1993 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 172 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.9 citations a year over 35 year(s) since 1993
Impact for its field and year 4 / 6 Cited 8.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 15 other studies in this library
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Lars Gustafson: h-index 44 (OpenAlex, whole career)
Institution's track record 1 / 3 Lund University: institution h-index 1,119 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 8401782)
Free to read 0 / 2 Behind a paywall — scores zero
Points 39 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 39 of the 96 points we could judge it on is 41 out of 100.
Total 41 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Later studies that cite this one

15 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Digital health tools from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Digital health tools

See all studies in Digital health tools →